Pulmonx Co. (NASDAQ:LUNG) Shares Sold by Atom Investors LP

Atom Investors LP lowered its stake in Pulmonx Co. (NASDAQ:LUNG) by 82.6% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 19,389 shares of the company’s stock after selling 92,305 shares during the quarter. Atom Investors LP’s holdings in Pulmonx were worth $161,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently added to or reduced their stakes in LUNG. FMR LLC grew its stake in Pulmonx by 11.2% in the 3rd quarter. FMR LLC now owns 5,872,882 shares of the company’s stock valued at $48,686,000 after acquiring an additional 591,859 shares during the period. PFM Health Sciences LP purchased a new position in shares of Pulmonx during the 3rd quarter worth $3,058,000. Millrace Asset Group Inc. purchased a new position in shares of Pulmonx during the 3rd quarter worth $1,390,000. Squarepoint Ops LLC raised its holdings in shares of Pulmonx by 261.2% during the 2nd quarter. Squarepoint Ops LLC now owns 144,409 shares of the company’s stock worth $916,000 after acquiring an additional 104,432 shares during the period. Finally, Susquehanna Fundamental Investments LLC purchased a new position in shares of Pulmonx during the 2nd quarter worth $477,000. Institutional investors and hedge funds own 91.04% of the company’s stock.

Analysts Set New Price Targets

Separately, Stifel Nicolaus reduced their price target on Pulmonx from $17.00 to $16.00 and set a “buy” rating on the stock in a report on Thursday, October 31st. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, Pulmonx currently has a consensus rating of “Moderate Buy” and a consensus price target of $14.67.

Insider Transactions at Pulmonx

In other news, Director Glendon E. French III sold 20,000 shares of the business’s stock in a transaction dated Thursday, October 17th. The stock was sold at an average price of $6.52, for a total transaction of $130,400.00. Following the completion of the transaction, the director now directly owns 1,091,974 shares of the company’s stock, valued at approximately $7,119,670.48. The trade was a 1.80 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, General Counsel David Aaron Lehman sold 5,497 shares of the business’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $6.19, for a total value of $34,026.43. Following the transaction, the general counsel now directly owns 197,851 shares of the company’s stock, valued at approximately $1,224,697.69. This represents a 2.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 69,873 shares of company stock valued at $485,870. 5.70% of the stock is currently owned by corporate insiders.

Pulmonx Stock Performance

NASDAQ LUNG opened at $6.53 on Thursday. The company has a market cap of $257.87 million, a P/E ratio of -4.44 and a beta of 0.69. The company has a debt-to-equity ratio of 0.40, a current ratio of 7.70 and a quick ratio of 6.77. The stock has a 50-day moving average of $6.77 and a two-hundred day moving average of $6.99. Pulmonx Co. has a 1-year low of $5.46 and a 1-year high of $14.84.

Pulmonx (NASDAQ:LUNG) last released its earnings results on Wednesday, October 30th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.07. The company had revenue of $20.39 million during the quarter, compared to the consensus estimate of $20.39 million. Pulmonx had a negative return on equity of 53.88% and a negative net margin of 72.01%. During the same period in the previous year, the company posted ($0.39) EPS. As a group, analysts anticipate that Pulmonx Co. will post -1.53 EPS for the current year.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.